New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
05:35 EDTBAYRY, AMGNBayer, Onyx reports NEXAVAR Phase 3 trial did not meet primary endpoint
Bayer HealthCare (BAYRY) and Onyx Pharmaceuticals, an Amgen subsidiary (AMGN), announced that an investigational Phase 3 trial of NEXAVAR tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival. The study, called RESILIENCE, evaluated the efficacy and safety of sorafenib in combination with capecitabine, an oral chemotherapeutic agent, compared to placebo plus capecitabine, in patients with HER2-negative breast cancer who are resistant to or have failed prior taxane therapy, and resistant to or failed anthracycline or for whom further anthracycline therapy is not indicated. Based on initial review of the data, the types of adverse events observed were generally comparable with those known for either sorafenib or capecitabine. Data from this study are expected to be presented at an upcoming scientific congress.
News For BAYRY;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
12:12 EDTBAYRYOncoMed cancer pipeline expanded with new candidate, says Piper Jaffray
Subscribe for More Information
08:37 EDTBAYRYOncoMed announces advancement small molecule Wnt pathway inhibitor
Subscribe for More Information
07:30 EDTAMGNSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
07:26 EDTAMGNInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
11:25 EDTBAYRYBayer said to not plan spin-off of Agrochem unit, Bloomberg reports
Subscribe for More Information
08:59 EDTAMGNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
08:11 EDTAMGNAmgen to host conference call
Subscribe for More Information
September 23, 2014
09:00 EDTBAYRYBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
September 22, 2014
09:02 EDTAMGNAmgen submits BLA to the FDA for immunotherapy blinatumomab
Subscribe for More Information
05:17 EDTBAYRYRegeneron announces EYLEA injection approved for myopic CNV treatment in Japan
Subscribe for More Information
September 19, 2014
07:35 EDTBAYRYZoetis seen as potential Bayer target after split announcement, Bloomberg says
Subscribe for More Information
September 18, 2014
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information
September 17, 2014
17:44 EDTBAYRYBayer plans separation of MaterialsSciences unit, WSJ says
Subscribe for More Information
08:03 EDTAMGNAmgen price target raised to $151 from $143 at Morgan Stanley
Morgan Stanley raised Amgen's price target to $151 based on increased brodalumab and AMG 416 expectations. Shares are Overweight rated.
September 16, 2014
07:31 EDTBAYRYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use